Prilenia Therapeutics names Frederick “Rick” Munschauer chief medical officer

• Forbion portfolio company Prilenia Therapeutics appointed Frederick (Rick) Munschauer as chief medical officer.
• Munschauer will help run PRECISE-HD, a registrational Phase 3 Huntington’s disease study, alongside PREVAiLS, a registrational Phase 3 ALS study.
• He most recently served as CMO at Emalex Biosciences, leading development of ecopipam to an FDA NDA submission for pediatric Tourette syndrome in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.